Rocket Pharmaceuticals, Inc. (RCKT) Reaches $20.89 After 6.00% Up Move; BILLERUD AB SHS SWEDEN (BLRDF) Shorts Up By 10.94%

May 30, 2018 - By Ash

BILLERUD AB SHS SWEDEN (OTCMKTS:BLRDF) had an increase of 10.94% in short interest. BLRDF’s SI was 342,700 shares in May as released by FINRA. Its up 10.94% from 308,900 shares previously. With 1,200 avg volume, 286 days are for BILLERUD AB SHS SWEDEN (OTCMKTS:BLRDF)’s short sellers to cover BLRDF’s short positions. It closed at $14.7 lastly. It is down 0.00% since May 30, 2017 and is . It has underperformed by 12.57% the S&P500.

The stock of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a huge mover today! The stock increased 4.45% or $0.89 during the last trading session, reaching $20.89. About 208,042 shares traded. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) has risen 192.71% since May 30, 2017 and is uptrending. It has outperformed by 180.14% the S&P500.The move comes after 8 months positive chart setup for the $824.75 million company. It was reported on May, 30 by Barchart.com. We have $22.14 PT which if reached, will make NASDAQ:RCKT worth $49.48M more.

BillerudKorsnäs AB provides fiber based packaging materials and packaging solutions in Sweden and internationally. The company has market cap of $. It operates through Packaging Paper, Consumer Board, and Corrugated Solutions divisions. It currently has negative earnings. The Packaging Paper segment offers kraft and sack paper for industrial, medical equipment, and consumer sectors; and pulp.

More notable recent Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) news were published by: Streetinsider.com which released: “Rocket Pharmaceuticals (RCKT) Highlights Updated Data from Phase 1/2 Gene Therapy Trial of RP-L102” on May 18, 2018, also Seekingalpha.com with their article: “Rocket Pharma’s lead candidate shows positive effect in Fanconi anemia” published on May 18, 2018, Seekingalpha.com published: “Key events next week – healthcare” on May 11, 2018. More interesting news about Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” published on May 17, 2018 as well as Benzinga.com‘s news article titled: “The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More” with publication date: May 13, 2018.

Rocket Pharmaceuticals, Inc., a multi-platform biotechnology company, focuses on the development of gene therapies for rare and devastating pediatric diseases. The company has market cap of $824.75 million.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Ash

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: